Prasinezumab

Prasinezumab
Monoclonal antibody
Type?
Targetα-Synuclein
Clinical data
Other namesNEOD002; NEOD-002; PRX002; PRX-002; RG7935; RG-7935; RO7046015; RO-7046015
Identifiers
CAS Number
DrugBank
UNII

Prasinezumab (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names NEOD002, PRX-002, RG-7935, RO-7046015) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which is under development for the treatment of Parkinson's disease.[1][2][3][4] No significant effect on disease progression was seen in a 52-week phase 2 clinical trial.[2] In any case, the trial was extended and development of the drug continues.[2] There have been concerns about research misconduct and data fabrication relevant to prasinezumab.[5] As of May 2024, prasinezumab is in phase 2 clinical trials for Parkinson's disease.[1] It is under development by Prothena Biosciences and Roche.[1]

  1. ^ a b c "Prasinezumab - Prothena Corporation/Roche". AdisInsight. 9 May 2024. Retrieved 26 September 2024.
  2. ^ a b c Manoutcharian K, Gevorkian G (March 2024). "Recombinant Antibody Fragments for Immunotherapy of Parkinson's Disease". BioDrugs. 38 (2): 249–257. doi:10.1007/s40259-024-00646-5. PMC 10912140. PMID 38280078.
  3. ^ Lasheen NN, Allam S, Elgarawany A, Aswa DW, Mansour R, Farouk Z (September 2024). "Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders". J Physiol Sci. 74 (1): 46. doi:10.1186/s12576-024-00933-4. PMC 11421184. PMID 39313800.
  4. ^ Teng JS, Ooi YY, Chye SM, Ling AP, Koh RY (2021). "Immunotherapies for Parkinson's Disease: Progression of Clinical Development". CNS Neurol Disord Drug Targets. 20 (9): 802–813. doi:10.2174/1871527320666210526160926. PMID 34042040.
  5. ^ Incorvaia, Darren (26 September 2024). "NIH neuroscience leader committed research misconduct, agency investigation finds". Fierce Biotech. Retrieved 26 September 2024.